![]() | |
Industry | Pharmaceutical; Psychedelic medicine |
---|---|
Founded | 2021 |
Founder | Ann Shulgin; Paul Daley; Nicholas Cozzi |
Website | shulginresearch |
Alexander Shulgin Research Institute (ASRI) is an organization developing novel psychedelic and entactogen drugs as potential pharmaceuticals, among other activities. [1] [2] [3] [4] [5] Its goal is to advance the scientific work and legacy of psychedelic chemist Alexander "Sasha" Shulgin and to complete his unfinished projects. [3] [4] [5]
The ASRI was informally established by Alexander Shulgin in the 1980s. [1] However, discussions to formally establish the institute began shortly after Shulgin's passing in 2014. [6] The organization was formally incorporated on April 19th, 2021, Bicycle Day, by Ann Shulgin, the late widow of Alexander Shulgin, and by psychedelic chemists and longtime Shulgin research colleagues Paul Daley and Nicholas Cozzi. [1] [2] [4] Cozzi was the organization's first president between 2020 and 2025. [2] He was succeeded by Daley in March 2025.[ citation needed ] As of April 2025, ASRI has filed and/or been granted several patents covering various entactogenic and psychedelic compounds. [7] [8] [9] [10] [11] Shulgin himself was not averse to intellectual property (IP) protection and held patents for drugs such as DOM, DOET, Ariadne, and methylone. [1] [12] [13]
Pharmaceutical candidates under development at ASRI include ASR-3001 (5-MeO-iPALT; a "second-generation, fast-acting tryptamine" said to produce an internal psychedelic state without sensory or visual disturbances) and ASR-2001 (2CB-5PrO; a phenethylamine-based non-hallucinogenic serotonin 5-HT2A receptor agonist). [1] [2] [14] [15] [16] [7] [8] XOB, a drug invented by Cozzi, is a dual-action serotonin 5-HT2A receptor antagonist and voltage-gated sodium channel blocker. [17] ASRI has more than 500 compounds in its collection, many of which were originally developed by Alexander Shulgin. [1]
A related initiative is the Alexander Shulgin Archiving Project (or The Shulgin Archive), which is a co-project with Erowid that began by 2007. [6] [12] An earlier group preceding the ASRI was "Team Shulgin", which was formed by 2010 and comprised Alexander and Ann Shulgin, Ann Shulgin's daughter Wendy Tucker (the editor of PiHKAL and TiHKAL and the head of Transform Press), Paul Daley, Tania Manning, and Greg Manning. [18] [19]
I first started paying regular visits to the Farm in order to play Go with Sasha. A few years ago, I began helping Team Shulgin with publishing and lending my entrepreneurial skills towards establishing the Alexander Shulgin Research Institute (ASRI). I've passed many hours at the Farm working on this Archiving Project.
New information has appeared in public revelations by Nick Sand and Tim Scully, and additional documentation emerged during the digitization process for the Alexander Shulgin Archiving Project, October 2015 through July 2022.
Team Shulgin (Sasha & Ann Shulgin, Paul Daley, Tania Manning) The Shulgin Index and Shulgin Legacy Project.
Paul Daley is part of a core group of people referred to as Team Shulgin by their friends, who help Ann and Sasha to carry on the legacy of their work. Team Shulgin includes Ann's daughter Wendy Tucker, who edited PIHKAL and the sequel,TIHKAL (Tryptamines I Have Known And Loved), and is the head of Transform Press, the publisher of Shulgin books; and Greg and Tania Manning, the Shulgin researchers/writers/archivists/personal assistants who live, work and travel with them.